The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) encompasses over 35 member companies and 80 scientifically driven working groups The IQ COVID19 Working Group has conducted two surveys aiming to gather IQ member companies’ experience with the impact of the COVID19 pandemic on the different aspects related to clinical trials conduct and design The two surveys collected data through July 2020 for Survey 1 and November 2021 for Survey 2 A total of 69 and 47 clinical trials were included in Surveys 1 and 2, respectively In Survey 1, 44% of trials were Phase 1 and approximately 50% were Phase 2 or 3 trials, with 45% of trials evaluating small molecules and 39% evaluating biologics In Survey 2, 57% of trials were Phase 1/clinical pharmacology trials and approximately 40% were patient trials (Phase 1b, 2, or 3), with 61% of trials being for small molecules and 35% for biologics Both surveys had representation from trials conducted in different geographic regions including North America, Europe, and Asia In Survey 1, the extent of missed doses or missed pharmacokinetic (PK) or pharmacodynamic (PD) samples in clinical trials due to the pandemic was small (≤ 10%) for most trials The top reasons in Survey 1 for missing doses or PK/PD data were the lack of access to clinic and patients deciding to skip visit due to the pandemic In Survey 2, while ~ 90% of Phase 1 trials started on time, the majority of responders (~70%) reported that it took longer time to complete the trial compared to prior to the pandemic Approximately 40% of clinical trials were reported to have reduced the number of study visits due to the pandemic The extent of missing doses or missing PK/PD samples was reported to be small in Survey 2, which is consistent with Survey 1 Key mitigation strategies which were implemented to minimize the extent of missing doses or samples were conducting remote study visits via telemedicine, use of local laboratories, allowing wider sampling window, at home sampling, or patient drive-through for sample collections Responders to Survey 2 indicated that future trials may implement patient-centric sampling, mostly through a mobile nurse collecting at-home samples